Stream Link: https://globalmeet.webcasts.com/starthere.jsp?ei=1715587&tp_key=30eee482e3
Program Description
Hypertrophic cardiomyopathy (HCM) is a complex heart condition that is often underdiagnosed, leading to inadequate treatment and causing significant health care burden. New treatments, such as cardiac myosin inhibitors, target the underlying causes of HCM and offer symptom relief to patients. Managed care providers must be familiar with these new therapies to facilitate access and improve clinical outcomes. This program will explore the inclusion of cardiac myosin inhibitors within updated guidelines for managing HCM, as well as the challenges and limitations of conventional therapeutic approaches. Beyond pharmacologic management strategies, managed care professionals will review and discuss data-driven models for reducing health-related complications and burdens associated with HCM.
Target audience: Managed care pharmacists
Type of activity: Application
Release date: April 16, 2025
Expiration date: May 24, 2025
Time to complete activity: 1.5 hours
Learner level: Foundational
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the prevalence of hypertrophic cardiomyopathy (HCM) and the clinical and economic burden of disease.
- Identify the pathophysiological targets of current therapies used in the management of HCM.
- Analyze the current treatment guidelines for HCM and the recent clinical trial data for new and emerging agents.
- Investigate managed care strategies that support evidence-based treatment in HCM that consider patient-specific factors, clinical guidelines, cost-effectiveness, and health equity principles within a collaborative care model.
Christine Cadiz, PharmD, MA, BCPS
Associate Clinical Professor
UC Irvine School of Pharmacy & Pharmaceutical Sciences
Irvine, California
Billy Schnell, PharmD
Manager, Clinical Strategy and Services
Abarca Health
Tampa, Florida
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-25-076-H01-P. The activity is available for CE credit through May 24, 2025.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Billy Schnell, PharmD, has the following financial relationships with commercial interests to disclose:
Clinical Account Manager: Abarca Health
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Christine Cadiz, PharmD, MA, BCPS
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Liza Patel, PharmD, RPh; Daphne Davis, PharmD, BCOP; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms